New small molecules targeting apoptosis and cell viability in osteosarcoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Osteosarcoma (OS) is the most common primary malignant bone tumor.
• Current standard treatments (chemotherapy, surgery) have limited efficacy in recurrent or metastatic disease.
• Novel therapeutic strategies are urgently needed for osteosarcoma.

Purpose of the Study:

• To identify novel small molecules selectively targeting osteosarcoma cells.
• To evaluate the efficacy of identified compounds in preclinical models.
• To explore potential mechanisms of action, including the role of p53.

Main Methods:

• Phenotypic high-throughput screening of a 25,000 small-molecule library.
• Assessing cell viability in osteosarcoma cell lines (U2OS, HOS, Saos-2), a liver cancer cell line (HepG2), and primary human osteoblasts (hOB).
• Measuring caspase 3 and 7 activity and comparing compound sensitivity to doxorubicin and staurosporine.

Main Results:

• Two novel small molecules were identified that selectively reduced osteosarcoma cell viability.
• These compounds did not affect hepatocellular carcinoma cells or primary osteoblasts.
• The identified molecules induced caspase 3 and 7 activity and showed greater efficacy than doxorubicin in OS cells.
• Sensitivity to compounds was reduced in p53-negative osteosarcoma cells, suggesting a role for p53.

Conclusions:

• The identified small molecules demonstrate selective cytotoxicity against osteosarcoma cells.
• These compounds represent promising candidates for developing more effective osteosarcoma therapies.
• Further investigation into the p53 pathway may inform future drug development for osteosarcoma.